Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Shevrin

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Health and Quality of Life Outcomes|November 25, 2003
Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI)Susan Yount, David Cella, Donald Banik, et al.
Psycho-Oncology|July 28, 2010
Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom IndexDavid E Victorson, Jennifer L Beaumont, Sarah K Rosenbloom, et al.
The Prostate|June 22, 2010
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude miceShubham Gupta, Yujuan Wang, Raquel Ramos-Garcia, et al.
Journal of Clinical Epidemiology|February 1, 2005
An item bank was created to improve the measurement of cancer-related fatigueJin-Shei Lai, David Cella, Kelly Dineen, et al.
Journal of Applied Measurement|December 31, 2005
Expansion of a physical function item bank and development of an abbreviated form for clinical researchRita K Bode, Jin-shei Lai, Kelly Dineen, et al.
Clinical Genitourinary Cancer|May 20, 2026
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate CancerDaniel Shevrin, Mathew Yang, Linda M Sabatini, et al.
The Prostate|September 10, 2009
Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor modelYujuan Wang, Shubham Gupta, Vi Hua, et al.
The Journal of Urology|December 3, 2014
5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapyLaura E Pascal, Khalid Z Masoodi, Katherine J O'Malley, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate CancerAnthony V Serritella, Daniel Shevrin, Elisabeth I Heath, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Health and Quality of Life Outcomes|November 25, 2003
Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI)Susan Yount, David Cella, Donald Banik, et al.
Psycho-Oncology|July 28, 2010
Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom IndexDavid E Victorson, Jennifer L Beaumont, Sarah K Rosenbloom, et al.
The Prostate|June 22, 2010
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude miceShubham Gupta, Yujuan Wang, Raquel Ramos-Garcia, et al.
Journal of Clinical Epidemiology|February 1, 2005
An item bank was created to improve the measurement of cancer-related fatigueJin-Shei Lai, David Cella, Kelly Dineen, et al.
Journal of Applied Measurement|December 31, 2005
Expansion of a physical function item bank and development of an abbreviated form for clinical researchRita K Bode, Jin-shei Lai, Kelly Dineen, et al.
Clinical Genitourinary Cancer|May 20, 2026
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate CancerDaniel Shevrin, Mathew Yang, Linda M Sabatini, et al.
The Prostate|September 10, 2009
Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor modelYujuan Wang, Shubham Gupta, Vi Hua, et al.
The Journal of Urology|December 3, 2014
5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapyLaura E Pascal, Khalid Z Masoodi, Katherine J O'Malley, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate CancerAnthony V Serritella, Daniel Shevrin, Elisabeth I Heath, et al.
Pageof 2